The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Study ID: NCT04266301
Brief Summary: This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high-risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with IPSS-R intermediate, high, very high risk MDS and CMML-2.
Detailed Description: This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2). The primary objective of this study is to compare overall survival (OS) in the MBG453 plus azacitidine arm versus placebo plus azacitidine arm where OS is the time from randomization until death due to any cause. Subjects will be randomized in a 1:1 ratio to treatment arms as follow: MBG453 800 mg IV Q4W plus azacytidine, Placebo IV Q4W plus azacitidine The randomization will be stratified into 4 groups: intermediate risk MDS, high risk MDS, very high risk MDS and CMML-2. All subjects who discontinue both study treatments will enter a long-term post-treatment follow-up including response and PRO assessments, and/or survival follow-up for up to 5 years after the last subject was randomized. Subjects will be treated until they experience progression of disease (including transformation to acute leukemia per WHO 2016 classification), experience unacceptable toxicity or discontinue the study treatment for other reasons. Continuation of study treatment beyond progression (excluding transformation to acute leukemia: continuation in this case is not possible) may be possible in selected subjects.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Yuma Regional Cancer Center, Yuma, Arizona, United States
University Of California LA ., Los Angeles, California, United States
Yale University School Of Medicine Smilow Cancer Hospital, New Haven, Connecticut, United States
Mayo Clinic Jacksonville ., Jacksonville, Florida, United States
University Of Miami ., Miami, Florida, United States
Northwestern University Div of Hematology Oncology, Chicago, Illinois, United States
Massachusetts General Hospital ., Boston, Massachusetts, United States
Hackensack University Medical Ctr SC, Hackensack, New Jersey, United States
Weill Cornell Medicine NY-Presb ., New York, New York, United States
University of Rochester Medical Ctr Univ Rochester JP Wilmot, Rochester, New York, United States
University of Virginia University of Virginia, Charlottesville, Virginia, United States
Novartis Investigative Site, Pilar, Buenos Aires, Argentina
Novartis Investigative Site, Woolloongabba, Queensland, Australia
Novartis Investigative Site, Clayton, Victoria, Australia
Novartis Investigative Site, Perth, Western Australia, Australia
Novartis Investigative Site, Graz, , Austria
Novartis Investigative Site, Innsbruck, , Austria
Novartis Investigative Site, Linz, , Austria
Novartis Investigative Site, Brasschaat, , Belgium
Novartis Investigative Site, Roeselare, , Belgium
Novartis Investigative Site, Florianopolis, SC, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Calgary, Alberta, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Vina del Mar, Valparaiso, Chile
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Shenzhen, Guangdong, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Suzhou, Jiangsu, China
Novartis Investigative Site, Chang Chun, Jilin, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Chengdu, , China
Novartis Investigative Site, Jinan, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Tianjin, , China
Novartis Investigative Site, Tianjin, , China
Novartis Investigative Site, Rionegro, Antioquia, Colombia
Novartis Investigative Site, Bogota, , Colombia
Novartis Investigative Site, Praha 2, Czech Republic, Czechia
Novartis Investigative Site, Hradec Kralove, CZE, Czechia
Novartis Investigative Site, Brno - Bohunice, , Czechia
Novartis Investigative Site, Praha, , Czechia
Novartis Investigative Site, Helsinki, , Finland
Novartis Investigative Site, Kuopio, , Finland
Novartis Investigative Site, Grenoble, , France
Novartis Investigative Site, Lille, , France
Novartis Investigative Site, Paris 10, , France
Novartis Investigative Site, Toulouse, , France
Novartis Investigative Site, Tours, , France
Novartis Investigative Site, Vandoeuvre Les Nancy, , France
Novartis Investigative Site, Velbert, North Rhine-Westphalia, Germany
Novartis Investigative Site, Dresden, Sachsen, Germany
Novartis Investigative Site, Augsburg, , Germany
Novartis Investigative Site, Duesseldorf, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Greifswald, , Germany
Novartis Investigative Site, Jena, , Germany
Novartis Investigative Site, Kiel, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Alexandroupolis, Evros, Greece
Novartis Investigative Site, Patras, , Greece
Novartis Investigative Site, Ahmedabad, Gujrat, India
Novartis Investigative Site, Faridabad, Haryana, India
Novartis Investigative Site, Madurai, Tamil NADU, India
Novartis Investigative Site, Kolkata, West Bengal, India
Novartis Investigative Site, Kolkata, West Bengal, India
Novartis Investigative Site, Delhi, , India
Novartis Investigative Site, Afula, , Israel
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Bologna, BO, Italy
Novartis Investigative Site, Catania, CT, Italy
Novartis Investigative Site, Firenze, FI, Italy
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Reggio Calabria, RC, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Fukuoka city, Fukuoka, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Isehara, Kanagawa, Japan
Novartis Investigative Site, Sendai city, Miyagi, Japan
Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan
Novartis Investigative Site, Osaka Sayama, Osaka, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Osaka, , Japan
Novartis Investigative Site, Yamagata, , Japan
Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Beirut, , Lebanon
Novartis Investigative Site, Vilnius, , Lithuania
Novartis Investigative Site, Kuching, Sarawak, Malaysia
Novartis Investigative Site, Kuala Lumpur, , Malaysia
Novartis Investigative Site, Pulau Pinang, , Malaysia
Novartis Investigative Site, Selangor, , Malaysia
Novartis Investigative Site, Mexico, Distrito Federal, Mexico
Novartis Investigative Site, Satelite, Edo Mexico, Mexico
Novartis Investigative Site, Morelia, Michoacan, Mexico
Novartis Investigative Site, Estado de Mexico, , Mexico
Novartis Investigative Site, Groningen, , Netherlands
Novartis Investigative Site, Muscat, , Oman
Novartis Investigative Site, Lisboa, , Portugal
Novartis Investigative Site, Porto, , Portugal
Novartis Investigative Site, Saint Petersburg, , Russian Federation
Novartis Investigative Site, St Petersburg, , Russian Federation
Novartis Investigative Site, Riyadh, , Saudi Arabia
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Sevilla, Andalucia, Spain
Novartis Investigative Site, Oviedo, Asturias, Spain
Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
Novartis Investigative Site, Badalona, Catalunya, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Valencia, , Spain
Novartis Investigative Site, Bern, , Switzerland
Novartis Investigative Site, Zürich, , Switzerland
Novartis Investigative Site, Hualien City, Hualien, Taiwan
Novartis Investigative Site, Kaohsiung, , Taiwan
Novartis Investigative Site, Liouying Township, , Taiwan
Novartis Investigative Site, Taichung, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Taoyuan, , Taiwan
Novartis Investigative Site, Songkhla, Hat Yai, Thailand
Novartis Investigative Site, Khon Kaen, THA, Thailand
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Chiang Mai, , Thailand
Novartis Investigative Site, Ankara, , Turkey
Novartis Investigative Site, Edirne, , Turkey
Novartis Investigative Site, Istanbul, , Turkey
Novartis Investigative Site, Izmir, , Turkey
Novartis Investigative Site, Samsun, , Turkey
Novartis Investigative Site, Portsmouth, Hants, United Kingdom
Novartis Investigative Site, Edinburgh, , United Kingdom
Novartis Investigative Site, Manchester, , United Kingdom
Novartis Investigative Site, Nottingham, , United Kingdom
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR